After The Bell

Share SHARE

The Centers for Disease Control confirmed the first case of Ebola in the U.S. late Tuesday afternoon. Sarepta Therapeutics Inc. (SRPT), which is one of several companies developing treatments for the disease, is now up 2.38 on 166K shares. Sarepta Therapeutics dropped during the first half hour of...

The Centers for Disease Control confirmed the first case of Ebola in the U.S. late Tuesday afternoon. NewLink Genetics Corp. (NLNK), which is developing a candidate Ebola vaccine, is now up 2.57 on 32K shares. NewLink Genetics traded to the downside for the bulk of Tuesday's session and closed lower...

The Centers for Disease Control confirmed the first case of Ebola in the U.S. late Tuesday afternoon. Biocryst Pharmaceuticals Inc. (BCRX), which is working to develop an Ebola treatment, is now up 1.62 on 78K shares. Biocryst Pharmaceuticals declined for the majority of Tuesday's session and closed...

Westport Innovations Inc. (WPRT) lowered its full year 2014 revenues forecast to between $130 million and $140 million after the bell Tuesday. The consensus estimate is for revenues of $178.71 million. The stock is now down 2.01 on 9K shares. Westport Innovations dipped in early trade Tuesday and...

Shares of SYNNEX Corp. (SNX) surged more than 8% in after hours trading after the business process outsourcing services provider reported forecast-beating third quarter results and issued an upbeat outlook for the fourth quarter. The company also said that its Board of Directors has approved the initiation...

Catalyst Pharmaceutical Partners (CPRX) announced after the bell Monday that both co-primary endpoints, as well as a secondary endpoint, in its Phase 3 clinical trial of Firdapse demonstrated that Firdapse was significantly superior to placebo. The stock is now up 0.58 after the bell. Catalyst Pharmaceutical...

SYNNEX Corp. (SNX) reported third quarter adjusted EPS of $1.59 after the close Monday, up from $1.33 in the prior year period. The consensus estimate was for EPS of $1.48. Fourth quarter adjusted EPS is expected to be between $1.66 and $1.71. Analysts are expecting EPS of $1.68. The stock is now up...

Cintas Corp. (CTAS) reported first quarter EPS of $0.93 after the bell Monday, up from $0.63 in the previous year. Analysts expected EPS of $0.75. Full year 2015 EPS is expected to be between $3.20 and $3.29. The consensus estimate is for EPS of $3.09. The stock is now up 0.65 on 20K shares. Cintas...

Cabot Oil & Gas Corp. (COG) climbed until mid-morning Friday and took out the session highs around mid-afternoon. The stock closed up by 0.72 at $32.15. Cabot Oil & Gas is attempting to recover from a week-long decline. The stock is now down 1.03 on 1.3 million shares after the close Friday.

Starboard Value LP stated Friday that it has acquired a significant ownership stake in Yahoo! Inc. (YHOO). Starboard also delivered a letter to both Yahoo CEO Marissa Mayer and its board, wherein it urged the company to seek a possible combination with AOL Inc. (AOL). Yahoo! spiked to the upside around...

The FDA announced after the close Friday that it has approved ILUVIEN for the treatment of diabetic macular edema. pSivida Corp. (PSDV) will now be entitled to a $25 million milestone from its licensee Alimera Sciences (ALIM). pSivida will also be entitled to 20% of the net profits from sales of ILUVIEN...

Alimera Sciences Inc. (ALIM) announced after the bell Friday that it received FDA approval for ILUVIEN. ILUVIEN is a treatment for diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure....

Shares of Nike Inc. (NKE) surged more than 7% in after hours trading after the world's largest athletic shoes and apparel maker reported forecast-beating first quarter results. Micron Technology, Inc., (MU) shares rose more than 3% in extended hours trading after the memory chip maker reported fourth...

Pharmacyclics Inc. (PCYC) and Servier announced after the bell Thursday that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat. Global development and commercialization rights will return...

Progress Software Corp. (PRGS) reported third quarter non-GAAP EPS of $0.39 after the close Thursday, up from $0.27 a year ago. Analysts expected EPS of $0.33. The company expects to report fourth quarter non-GAAP EPS of $0.44 to $0.47 and between $1.47 and $1.50 for the full year. The consensus estimates...